A share price of Fate Therapeutics Inc [FATE] is currently trading at $1.06, up 13.34%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The FATE shares have gain 40.79% over the last week, with a monthly amount glided 12.35%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Fate Therapeutics Inc [NASDAQ: FATE] stock has seen the most recent analyst activity on November 18, 2024, when BofA Securities upgraded its rating to a Neutral. Previously, Piper Sandler upgraded its rating to Overweight on June 17, 2024, and elevated its price target to $6. H.C. Wainwright downgraded its rating to a Neutral and decreased its price target to $7 on January 24, 2023. Wedbush downgraded its rating to a Neutral and reduced its price target to $7 on January 06, 2023. Truist downgraded its rating to Hold for this stock on January 06, 2023, and downed its price target to $7. In a note dated January 06, 2023, Stifel downgraded an Hold rating on this stock and revised its target price from $107 to $5.30.
Fate Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $0.66 and $6.37. Currently, Wall Street analysts expect the stock to reach $4 within the next 12 months. Fate Therapeutics Inc [NASDAQ: FATE] shares were valued at $1.06 at the most recent close of the market. An investor can expect a potential return of 277.36% based on the average FATE price forecast.
Analyzing the FATE fundamentals
Trailing Twelve Months sales for Fate Therapeutics Inc [NASDAQ:FATE] were 13.63M which represents 10.98% growth. Gross Profit Margin for this corporation currently stands at -1.89% with Operating Profit Margin at -15.43%, Pretax Profit Margin comes in at -13.66%, and Net Profit Margin reading is -13.66%. To continue investigating profitability, this company’s Return on Assets is posted at -0.42, Equity is -0.5 and Total Capital is -0.52. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.27.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.9553 points at the first support level, and at 0.8506 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.1173, and for the 2nd resistance point, it is at 1.1746.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Fate Therapeutics Inc [NASDAQ:FATE] is 7.58. Also, the Quick Ratio is 7.58, while the Cash Ratio stands at 0.94. Considering the valuation of this stock, the price to sales ratio is 8.91, the price to book ratio is 0.38.
Transactions by insiders
Recent insider trading involved Wolchko J Scott, Former Officer and Director, that happened on Mar 06 ’25 when 0.11 million shares were purchased., Bressi Jerome Charles completed a deal on Jan 10 ’25 to sell 5980.0 shares. Meanwhile, TAHL CINDY sold 5654.0 shares on Jan 10 ’25.
